Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for chagas: experimental drug aims to wipe out parasites

NCT ID NCT06632600

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests an experimental drug called LXE408 in 130 adults with chronic Chagas disease who do not have severe organ damage. The goal is to see if LXE408 can clear or reduce the parasite level in the blood over 6 months, compared to placebo and standard treatment. Participants take the drug by mouth for 28 days, and researchers check for parasites using a sensitive test (PCR) at several time points.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LXE408 (an experimental oral drug)
What this could lead to
If successful, this could provide a new treatment option for chronic Chagas disease, potentially reducing parasite levels and preventing disease progression.
What could go wrong
This is an early Phase 2 trial with only 130 participants, so results may not apply to everyone. The drug may not clear parasites as hoped, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHAGAS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chagas disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHAGAS DISEASE

Contacts and locations

Locations

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030-3411, United States

  • Boston Medical Center

    RECRUITING

    Boston, Massachusetts, 02118, United States

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, C1221ADC, Argentina

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, C1407FWE, Argentina

  • Novartis Investigative Site

    RECRUITING

    Córdoba, Córdoba Province, X5016KEH, Argentina

  • Novartis Investigative Site

    RECRUITING

    Caba, C1015ABO, Argentina

  • Novartis Investigative Site

    RECRUITING

    Corrientes, W3400CDS, Argentina

  • Novartis Investigative Site

    RECRUITING

    Formosa, P3600KGC, Argentina

  • Novartis Investigative Site

    RECRUITING

    Montes Claros, Minas Gerais, 39401-001, Brazil

  • Novartis Investigative Site

    RECRUITING

    Recife, Pernambuco, 50100-060, Brazil

  • Novartis Investigative Site

    RECRUITING

    Rio de Janeiro, Rio de Janeiro, 21040-360, Brazil

  • Novartis Investigative Site

    RECRUITING

    São Caetano do Sul, São Paulo, 09521-160, Brazil

  • Novartis Investigative Site

    RECRUITING

    Barranquilla, Atlántico, 080005, Colombia

  • Novartis Investigative Site

    RECRUITING

    Yopal, Casanare Department, 850009, Colombia

  • Novartis Investigative Site

    RECRUITING

    Bogotá, 110131, Colombia

  • Novartis Investigative Site

    RECRUITING

    Bogotá, 111411, Colombia

  • Novartis Investigative Site

    RECRUITING

    Floridablanca, 681017, Colombia

  • Novartis Investigative Site

    RECRUITING

    San Gil, 684031, Colombia

  • Olive View UCLA Educ and Res Ins

    RECRUITING

    Sylmar, California, 91342, United States

  • University of Florida Shands

    RECRUITING

    Gainesville, Florida, 32610-0486, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.